NCT03919513

Brief Summary

Inspiratory muscle training(IMT) was one of the widely used pulmonary rehabilitation method in COPD patients.However, when the respiratory muscles are fatigue without sufficient rest, IMT may increase muscle fatigue and aggravate muscle damage. Noninvasive positive pressure ventilation (NPPV) is another important strategy of pulmonary rehabilitation which could overcome airway resistance and reduce respiratory work, improve respiratory muscle fatigue. Therefore, the purpose of this study was to explore the effective of the "IMT - NPPV sequential" rehabilitation method, that is, first inspiratory muscle training, followed by respiratory muscle resting (non-invasive positive pressure ventilation).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 18, 2019

Completed
13 days until next milestone

Study Start

First participant enrolled

May 1, 2019

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

March 13, 2024

Status Verified

January 1, 2019

Enrollment Period

2.8 years

First QC Date

April 4, 2019

Last Update Submit

March 12, 2024

Conditions

Keywords

IMT,NPPV,Pulmonary rehabilitation

Outcome Measures

Primary Outcomes (1)

  • Respiratory muscle strength(composite outcome measure)

    Currently, the maximal inspiratory pressure (PImax) and maximal expiratory pressures(PEmax) are measured by a digital manometer (AZ-8205, AZ Instrument, Taichung City, Taiwan)and combined to evaluate respiratory muscle function.

    Change from baseline to 8 weeks

Secondary Outcomes (4)

  • Diaphragmatic function

    Change from baseline to 8 weeks

  • Symptom Evaluation(composite outcome measure)

    Change from baseline to 8 weeks

  • Pulmonary function(composite outcome measure)

    Change from baseline to 8 weeks

  • Exercise capacity

    Change from baseline to 8 weeks

Study Arms (2)

respiratory muscle weakness

EXPERIMENTAL

Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.

Device: inspiratory pressure threshold device

normal respiratory muscle

EXPERIMENTAL

Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.

Device: inspiratory pressure threshold device

Interventions

The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.

Also known as: CPAP
normal respiratory musclerespiratory muscle weakness

Eligibility Criteria

Age40 Years - 80 Years
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with pulmonary function test of forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) \< 70% after inhalation of bronchial dilation agent. Patients in a clinically stable state.

You may not qualify if:

  • Patients were excluded if they had other respiratory diseases ,or evidence of pneumothorax or mediastinal emphysema and pacemaker installed.
  • Patients with acute cardiovascular event and severe cor pulmonale. Patients with poor compliance. An Other causes of diaphragmatic dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhujiang Hospital,Southern Medical Universicity

Guangzhou, Guangdong, 510282, China

Location

Study Officials

  • Chen Xin, Doctor

    Zhujiang Hospital,Southern Medical Unversity

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2019

First Posted

April 18, 2019

Study Start

May 1, 2019

Primary Completion

February 1, 2022

Study Completion

May 1, 2022

Last Updated

March 13, 2024

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations